Analyst Price Target is $7.00
▲ +96.08% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anixa Biosciences in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 96.08% upside from the last price of $3.57.
Current Consensus is
Strong Buy
The current consensus among 2 investment analysts is to buy (strong buy) stock in Anixa Biosciences. This Strong Buy consensus rating has held steady for over two years.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More